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Abstract
Background: This study aimed to show that SHOX2 DNA methylation is a tumor marker in patients with
suspected lung cancer by using bronchial fluid aspirated during bronchoscopy. Such a biomarker would be
clinically valuable, especially when, following the first bronchoscopy, a final diagnosis cannot be established by
histology or cytology. A test with a low false positive rate can reduce the need for further invasive and costly
procedures and ensure early treatment.
Methods: Marker discovery was carried out by differential methylation hybridization (DMH) and real-time PCR. The
real-time PCR based HeavyMethyl technology was used for quantitative analysis of DNA methylation of SHOX2
using bronchial aspirates from two clinical centres in a case-control study. Fresh-frozen and Saccomanno-fixed
samples were used to show the tumor marker performance in different sample types of clinical relevance.
Results: Valid measurements were obtained from a total of 523 patient samples (242 controls, 281 cases). DNA
methylation of SHOX2 allowed to distinguish between malignant and benign lung disease, i.e. abscesses,
infections, obstructive lung diseases, sarcoidosis, scleroderma, stenoses, at high specificity (68% sensitivity [95% CI
62-73%], 95% specificity [95% CI 91-97%]).
Conclusions: Hypermethylation of SHOX2 in bronchial aspirates appears to be a clinically useful tumor marker for
identifying subjects with lung carcinoma, especially if histological and cytological findings after bronchoscopy are
ambiguous.
Background
Lung cancer is the second most common cancer in both
men and women representing about 15% of all cancer
diagnoses [1]. In the absence of screening, lung cancer
patients either exhibit symptoms or are accidentally
diagnosed by clinical imaging performed for other indi-
cations. Patients suspected of having malignant lung dis-
ease usually undergo clinical investigation (workup)
including CT-scanning of the thorax and bronchoscopy,
w h i c hi sm a i n l yu n d e r t a k e ni nt h o s ei n d i v i d u a l sw i t h
central tumours. The latter is the method of choice for
confirming the diagnosis of a suspected lung neoplasm
by pathological assessment of tissue or a cytological spe-
cimen obtained during the procedure.
The prevalence of lung cancer in this group of
patients investigated for suspected lung cancer is
approximately 30-40% (personal communication Prof.
Field). Establishing a final diagnosis after the first
bronchoscopy fails in about half of these patients [2],
triggering additional invasive diagnostic procedures.
Even when signs, symptoms and radiological findings
are such that the clinical diagnosis of malignant lung
disease appears obvious, it often takes considerable
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suitable for definitively confirming the presence of
malignant disease.
Ambiguous results (i.e. the presence of malignancy
cannot be confirmed) following bronchoscopy are not
uncommon, e.g. because the tumor is not visible endos-
copically and cells obtained by brushing or aspiration do
not allow the pathologist to confirm or exclude malig-
nancy. In these cases, several additional diagnostic pro-
cedures are available, each with its own pros and cons:
￿ Histology from needle biopsy (transbronchial or
transthoracic) or surgical intervention is the gold
standard for establishing the diagnosis of malignant
disease. These procedures are invasive and may
cause complications like pneumothorax and bleed-
ings [3,4].
￿ Repeated CT-scan after about 12 weeks is able to
detect growth of a lesion. This is a means for
increasing the specificity of CT-scanning for detect-
ing malignancy, but it is only a surrogate marker
and may lead to a delay in establishing the diagnosis.
￿ PET scanning is clinically valuable for identifying
areas of hypermetabolism. It can only detect lesions
with a diameter of about 1 cm or more and is cur-
rently an expensive investigative method [5]. Addi-
tionally, increased metabolism is not a cancer
specific phenomenon.
Biomarkers have great potential for improving the
management of lung cancer in clinical routine. So far,
several biomarkers from various sources such as genet-
ics, proteomics, and epigenetic approaches are in use for
clinical research purposes [6-8]. The analysis of DNA
methylation biomarkers is an emerging field that pro-
vides promising potential for improving the clinical pro-
cess of lung cancer diagnosis [9-13]. Methylation of
DNA is an important epigenetic process involved in fun-
damental biological events such as development and cell
differentiation [14]. Aberrant DNA methylation has
been reported to play a major role in carcinogenesis
[15], suggesting that DNA methylation analysis may be
a valuable source for cancer biomarkers [16].
In the presented study, SHOX2 methylation was iden-
tified as a biomarker capable of reliably differentiating
between lung tumor and normal tissues. This genome
wide discovery approach was carried out using differen-
tial methylation hybridization (DMH) technology [17]. A
real-time PCR based assay for highly sensitive and accu-
rate quantification of methylated SHOX2 copies in a
background of unmethylated DNA was developed. This
assay was then used to quantify the SHOX2 DNA
methylation in bronchial aspirates from 523 patients to
investigate its ability to identify patients with lung
cancer in a population of individuals with suspected
lung cancer. A calibrator, a DNA sample with known
methylation, was used in order to normalize for lot-to-
lot and site-to-site variability and therefore to allow for
routine clinical usage of the test. SHOX2 DNA methyla-
tion was shown to reliably detect cancer patients at high
specificity in a group of patients with benign lung dis-
eases, i.e. abscesses, infections, obstructive lung diseases,
sarcoidosis, scleroderma and stenoses, who underwent
the same clinical workup for suspected lung cancer.
Methods
Patients
Bronchial aspirates were collected at two medical centres
with appropriate written consent under approval of the
local ethics committees. 246 fresh-frozen specimens were
provided by the Charité University Hospital (Berlin, Ger-
many); 388 Saccomanno-fixed specimens came from the
Roy Castle Lung Cancer Research Program [18] (Cancer
Research Centre, Liverpool, UK). All patients donating
samples were investigated for suspected lung cancer in the
respective clinics. 141 of the fresh-frozen sample speci-
mens showed cytology negative result after bronchoscopy.
Samples from 523 patients passed the sample quality con-
trol acceptance criterion as described in chapter ‘Data and
Statistical Analysis’ and were suited for analyzing the
SHOX2 DNA methylation. The characteristic of this
population is described in more detail in Table 1.
Bronchial samples were collected during bronchoscopy
by aspiration with a flexible bronchoscope from the
region of the suspicious lesion after injecting 10-20 ml
of isotonic saline solution and prior to starting any can-
cer specific treatment, if applicable.
The diagnosis of bronchial carcinoma was confirmed
by one or more of the following approaches: cytology or
histology from biopsy or surgery specimen. Cases have
been selected to include a high number of stage I or II
(UICC) disease and to represent the main NSCLC his-
tology types. Patients that underwent workup for sus-
pected lung cancer in the same time period and at the
same clinics, did not show any evidence of malignant
lung disease and had a minimum lung cancer free survi-
val of 12 months were considered as the ‘control’ group
of patients for this study.
Samples fixed with Saccomanno’s reagent were stored
at room temperature for up to 12 years. The Median age
of Cases and Controls was 67 and 65 years respectively.
For frozen storage, the unfixed aspirates were centri-
fuged according to clinical routine procedures and the
pellets were stored at -80°C for up to 7 years.
Differential Methylation Hybridization (DMH)
Differential methylation hybridization (DMH) for gen-
ome-wide DNA methylation profiling using a CpG
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rich DNA fragments was carried out as previously
described [19].
Sample and Calibrator Preparation
A calibrator sample with known methylation level (1%)
and known total DNA (50 ng) content was prepared by
mixing bisulfite converted DNA from sperm with bisul-
fite converted methylated DNA. DNA extraction from
sperm and the bisulfite conversion of sperm DNA and
methylated DNA was carried out as previously
described [20].
DNA from bronchial aspirates was isolated by means
of the QIAamp® DNA Micro Kit (Qiagen) using a
modified tissue protocol (Kit handbook). Bisulfite con-
version of DNA was performed using the EpiTect Kit
(Qiagen).
Real-Time PCR
Real-time PCR (SYBR Green Assay) for the Analysis of
DNA from Tissue Specimens. PCR was carried out using
the QuantiTect Multiplex Kit (Qiagen, Hilden, Gemany)
with 0.3 μM of each primer (forward: GTTTTTTGGA-
TAGTTAGGTAAT, reverse: CCTCCTACCTTC-
TAACCC), 1 μM blocker (TAATTTTTGTTTTGTTTG
TTTGATTGGGGTTGTATGA-SpacerC3), 10 ng DNA
template (quantified via UV spectrophotometry) and
1:40,000 diluted SYBR Green I DNA dye (Biozym Scien-
tific, Oldendorf, Germany) in 20 μl per reaction. Real-
time PCR was performed on the LC480 platform (Roche
Diagnostics, Mannheim, Germany) with the following
program: 95°C/10 min, 45 cycles with 95°C/10 sec, 56°
C/30 s, 72°C/10 and 82.5°C/5 s (detection step).
R e a l - t i m eP C R( P r o b eA s s a y )f o rt h eA n a l y s i so fD N A
from Lavage Specimens. Real-time PCR assays were
comprised of two independent reactions: a total quanti-
fication assay for quantification of total input DNA and
an HM assay [21] for quantification of methylated target
template. The total quantification assay was composed
of two methylation-unspecific oligonucleotides and a
scorpion primer unspecific for DNA methylation. The
methylation quantification assay (HM assay) uses two
methylation-unspecific primers, two methylation-specific
blockers (one for each primer) and a scorpion primer
specific for methylated DNA. The PCR were done in 20
μl volumes (1 × QuantiTect Multiplex PCR NoROX Kit
[Qiagen], DNA [0.25 μl DNA from fresh-frozen and 1
μl from Saccomanno-fixed specimens] and oligonucleo-
tides [Table 2]).
PCR were performed using a 7900HT Fast Real-Time
PCR (Applied Biosystems, CA, USA) using the following
temperature profile: 15 min/95°C and 45 cycles with
15s/95°C and 30s/58°C.
Data and Statistical Analysis
For each sample a relative methylation value was deter-
mined using the ΔΔCT method [22,23] as follows:
ΔΔCTSample = ΔCTSample -C T Calibrator, where ΔCTSample =
CTSample/Total Quantification Assay -C T Sample/Methylation Quanti-
fication Assay and ΔCTCalibrator =C T Calibrator/Total Quantifica-
tion Assay -C T Sample/Methylation Quantification Assay. ΔΔCTs
were measured in triplicates. Sample quality acceptance
criterion: Samples were excluded from the study when
CTSample/Total Quantification Assay > (CTCalibrator/Total Quantifica-
tion Assay + 4). Since the sample contained 50 ng total
DNA, this excludes samples with less than approximately
3 ng input DNA into the PCR when assuming a PCR effi-
ciency of 100%.
A methylation cut-off was assigned for dichotomiza-
tion of the methylation value. Samples having a ΔΔCT
value above the cut-off were labeled positive, all others
Table 1 Characteristics of the patient population
Total Cases Controls
Age 523
(100%)
281
(100%)
242
(100%)
≤ 50 Years 59 (11%) 15 (5%) 44 (18%)
51-60 Years 110 (21%) 59 (21%) 51 (21%)
>60 Years 344 (66%) 206 (73%) 138 (57%)
Unknown 10 (2%) 1 (0%) 9 (4%)
Median Age 66 67 65
Age Range 23-90 37-90 23-85
Smoking Habits
Non-smokers 90 (17%) 21 (7%) 69 (29%)
Smokers (Current and Former) 320 (61%) 213 (76%) 107 (44%)
Unknown Smoking Status 113 (22%) 47 (17%) 66 (27%)
Range Packs/Years (Smokers
only)
0-171 0-171 0-141
Median Packs/Years (Smokers
only)
32 40 10
Mean Packs/Years (Smokers
only)
34 42 22
Histology Subtype
Squamous Cell Carcinoma x 103 (37%) x
Adenocarcinoma x 109 (39%) x
NSCLC NOS x 37 (13%) x
SCLC x 29 (10%) x
Other/Unknow x 3 (1%) x
Stage (UICC)
I x 59 (21%) x
II x 43 (15%) x
III x 108 (38%) x
IV x 62 (22%) x
Unknown x 9 (3%) x
Clinical data of the 523 analyzed patient samples (281 [54%] Cases, 242 [46%]
Controls). 111 samples (68 Saccomanno-fixed cases, 4 fresh-frozen cases, 34
Saccomanno-fixed controls, 5 fresh-frozen controls) failed the sample quality
control because their DNA yield was too low. They were excluded from
analysis and are not included in this table.
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false positive rate to less than 5% for benign samples.
The performance of the assay was reported by means
of sensitivity and specificity. Sensitivity is defined as the
ratio of correctly assigned positive lung cancer samples
in all lung cancer samples. Specificity is defined as the
ratio of correctly assigned negative samples in all nor-
mal/benign lung samples. Sensitivity and specificity esti-
mates are reported as frequency estimates with 95%
confidence intervals based on binomial distributions.
Results
Lung tumor specimens from 35 patients (14 adenocarci-
noma, 11 squamous, 5 large, and 5 small cell lung carci-
noma) and 20 normal lung tissue samples were analyzed
using DMH technology, a method for genome-wide
methylation profiling. DNA methylation of SHOX2 was
identified as a biomarker capable of differentiating
between lung cancer tissues and normal tissues (t-test
p-value = 0.0003, Wilcoxon Rank-Sum test p-value =
0.0006). A SYBR Green real-time PCR assay, located in
close proximity to the SHOX2 DMH amplicon, was
designed to confirm the findings from the DMH analy-
sis. Left-over DNA for SYBR Green real-time PCR ana-
lysis was available from 12 normal lung tissues and 11
lung cancer tissues (4 adenocarcinoma, 4 squamous, and
3 small cell lung carcinoma). Figure 1 shows the results
of the analyses and location of the DMH and the real-
time PCR amplicon. Both assays are located in a CpG-
rich region around the transcription start site of the b
variant of SHOX2 (SHOX2b, NM_003030). Ten out of
11 tumor tissues showed higher methylation of the
SHOX2 gene as compared to the normal lung tissues
indicated by lower CT values (t-test p-value < 0.0001,
Wilcoxon Rank-Sum test p-value = 0.0044). One tumor
showed no SHOX2 DNA methylation. The highest
methylation levels were found in small cell and squa-
mous cell carcinomas.
Ar e a lt i m eP C Ra s s a yf o rt h er e l a t i v ea n ds e n s i t i v e
detection of methylated SHOX2 DNA in a background
of high amounts of unmethylated DNA was developed.
The technical performance of the assay is shown in
Figure 2. Different amounts (3.1 - 10,000 pg) of bisulfite
converted artificially methylated DNA were spiked into
a background of 50,000 pg unmethylated DNA from
sperm in order to characterize the performance of the
assays. The amount of 3.1 - 10,000 pg methylated DNA
correspond to the DNA content from approximately
0.5 - 1,600 diploid cells. The assay allowed for the reli-
able detection of 25 pg (≈ f o u rd i p l o i dc e l l s )o fm e t h y -
lated DNA in a background of 50,000 pg (≈ 8,000
diploid cells) unmethylated DNA, respectively. Lower
amounts of methylated DNA are sporadically detected
as expected due to statistical reasons when analyzing
single copies of DNA.
The assay was used to quantify the DNA methylation
in 634 fresh-frozen and Saccomanno-fixed bronchial
aspirate samples. 111 samples (68 Saccomanno-fixed
cases, 4 fresh-frozen cases, 34 Saccomanno-fixed con-
trols, 5 fresh-frozen controls) failed the sample quality
control because their DNA yield was too low. These were
excluded from analysis. The results of the remaining 523
patient samples are shown in Table 3 and Figure 3. Back-
ground DNA methylation of the SHOX2 gene was found
in most of the samples necessitating the implementation
of the clinical cut-off to dichotomize the quantitative
methylation value into a qualitative result (test negative
or test positive, Figure 3A). Using a cut-off of ΔΔCT =
-4.56, which corresponds to approximately 0.04% methy-
lation, allowed for detection in 68% of cancer patients
with high specificity (95%). Applying lower cut-offs for
patients stratification led to an increasing sensitivity at
decreasing specificity (Figure 3B). The resulting AUC of
the ROC was 0.86 (Figure 3C).
The performance of the SHOX2 biomarker was further
investigated with respect to the histological subtype (ade-
nocarcinoma, squamous cell carcinoma, other) and the
s t a g e( I - I V ,U I C C ,T a b l e3 ) .T h es e n s i t i v i t ys l i g h t l y
increased at a higher stage. Overall lower sensitivity was
found for adenocarcinoma as compared to the other sub-
types. The tumor marker performance was notably good
in the subgroups of squamous cell carcinoma and SCLC,
with sensitivities of 82% and 97%, respectively. This is in
concordance with the results from the DMH study where
Table 2 Oligonucleotide specifications
Concentration [μM]
Total Quantification Assay Methylation Quantification Assay Sequence (5’ ® 3’)
0.3 0.5 GTTTTTTGGATAGTTAGGTAAT
0.15 0.15 CCTCCTACCTTCTAACCC
0.15 NA 6-FAM-CCGGGGTTGTATGAGTATAGGCCCCGG-BHQ1-C18-CCTCCTACCTTCTAACCC
NA 0.15 6-FAM-CCGGGGTTGTATGAGTATAGGCCCCGG-BHQ1-C18-CCTCCTACCTTCTAACCC
NA 1 TAATTTTTGTTTTGTTTGTTTGATTGGGGTTGTATGA-SpacerC3
NA 1 ACCCAACTTAAACAACAAACCCTTTA-SpacerC3
All oligonucleotides were supplied from biomers.net GmbH, Ulm, Germany.
Schmidt et al. BMC Cancer 2010, 10:600
http://www.biomedcentral.com/1471-2407/10/600
Page 4 of 9overall higher methylation was found in squamous cell
carcinoma and SCLC (Figure 1).
Cytological results were available from 162 patient
samples of which 156 samples passed the quality criter-
ion. An analysis with regard to cytology (Table 4)
revealed that SHOX2 DNA methylation made it possible
to identify 62% of cases which were classified as cytolo-
gically negative.
Methylation values and detailed clinical data for all
patients can be found in Additional file 1: Patient data
overview.
Discussion
DNA methylation has been shown to play an important
role in carcinogenesis [15] and DNA methylation altera-
tions are therefore among the most promising candi-
dates in biomarker research. Several previous studies
specifically targeted DNA methylation biomarkers for
their potential to improve clinical lung cancer manage-
ment [9-11,24,25].
T h eo b j e c t i v eo ft h i ss t u d yw a st os h o wt h a tS H O X 2
DNA methylation is a useful tumor marker to aid the
diagnostic workup for suspected lung cancer. The objec-
tive of this workup is to diagnose and stage patients
using the safest, least invasive and affordable
method [26]. In today’s clinical practice, a variety of
Figure 1 Location and results of the DMH and real-time PCR assays used for discovery and confirmation of SHOX2 DNA methylation
as a lung cancer biomarker. Tissue samples from 20 normal lungs and 35 lung tumors (14 adenocarcinoma, 11 squamous, 5 large, and 5 small
cell lung carcinoma) were analyzed by DMH. Results were confirmed using a SYBR Green HM real-time PCR assay.
Figure 2 Analytical assay performance. Analytical performance of
the quantitative real time PCR assay for quantifying SHOX2 DNA
methylation. Different amounts of methylated DNA (3.1 - 10,000 pg)
were spiked into a background of 50,000 pg unmethylated DNA.
Number of replicates: Sixteen (0 and 3.1 pg), eight (6.2-200 pg) and
three (1,250-10,000), respectively.
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due to their shortcomings, e.g. the invasiveness or the
limitations in diagnostic performance [27], there is a
need for improvement by additional diagnostic tools.
One way of achieving this goal is to use tumor markers
providing additional information based on existent
material yielded from diagnostic procedures.
The most appropriate sample for biomarker studies in
lung cancer is bronchial aspirate because of its general
availability in routine clinical practice. Bronchial fluid or
alternatively bronchial brushings are collected with little
risk and extra effort during the first bronchoscopy,
which is performed as an integral part in the diagnostic
workup.
The material is derived predominantly from the cir-
cumscribed clinical region of interest with little contam-
ination from other parts of the body. After cytological
analysis by a pathologist, there is usually sufficient left-
over material to extract DNA for methylation analysis.
Despite many studies showing a clinical value of spu-
tum samples [28,29], itsu s eh a sn o tb e e nw i d e l y
adopted in clinical routine, which thus limits their uti-
lity. A similar situation is also seen in blood, where the
total amount of lung derived DNA and the fraction of
tumor DNA contained in a sample are expected to be
lower than in aspirates. In addition, blood plasma con-
tains a complex mixture of DNA originating potentially
f r o ma n yp a r to ft h eb o d y .O t h e rt u m o r s ,e . g .c o l o n
tumors, will probably release tumor cells and tumor
DNA into the blood stream as well. In contrast, tumor
cells and tumor DNA found in the lungs are most likely
from lung tumors or lung metastases and therefore lead
to an increased specificity for lung cancer due to the
choice of a lung specific analyte. Epigenetic inactivation
of tumor supressor genes is critical to the pathogenesis
of cancers and some DNA methylation biomarkers, e.g.
RASSF1A, are known to be methylated in several differ-
ent tumor types, i.e. lung, breast, prostate, glioma,
Table 3 Subtype analysis
Histology
Tumor Stage Adeno-carcinoma Squamous Cell Carcinoma NSCLC NOS SCLC Other/Unknown All
Stage I 10/32 (31%) 19/24 (79%) 3/3 (100%) -/- -/- 32/59 (54%)
Stage II 7/17 (41%) 20/21 (95%) 2/3 (67%) 2/2 (100%) -/- 31/43 (72%)
Stage III 20/34 (59%) 36/45 (80%) 16/22 (73%) 6/6 (100%) 1/1 (100%) 79/108 (73%)
Stage IV 12/23 (52%) 6/9 (67%) 4/8 (50%) 20/21 (95%) 0/1 (0%) 42/62 (68%)
Stage unknown 2/3 (67%) 3/4 (75%) 1/1 (100%) -/- 0/1 (0%) 6/9 (67%)
All 51/109 (47%) 84/103 (82%) 26/37 (70%) 28/29 (97%) 1/3 (33%) 190/281 (68%)
Stage and histology specific performance of the SHOX2 DNA methylation biomarker in 523 bronchial aspirates from patients with suspected lung cancer.
Figure 3 Clinical performance of the SHOX2 DNA methylation biomarker. Valid measurements were obtained from 523 patients (281 cases,
242 controls). A: SHOX2 DNA methylation values measured in cases (red) and controls (black). Low ΔΔCT indicate a low SHOX2 DNA
methylation. A ΔΔCT = 0 refers to a sample showing the same methylation as the calibrator DNA (1%). B: Resulting sensitivity and specificity
when using alternative cut-offs for patient stratification. C: Receiver Operating Characteristic (ROC) and the resulting Area Under the Curve (AUC).
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Thus, the biological marker requirements for analysing
blood are higher and the markers need to be truly speci-
fic for lung tumor DNA to ensure a highly specific lung
cancer test.
One of the most common fixatives used for aspirates
in clinical practice is Saccomanno’s reagent. It allows for
the storage of samples at ambient temperature for sev-
eral years, thereby maintaining morphological character-
istics and is known to preserve DNA and has been
previously shown to be suitable for molecular biological
analysis [32,33]. The combination of the characteristics
described above makes bronchial aspirates a preferred
choice of material for developing a diagnostic test for
lung cancer based on DNA methylation.
In this study, DNA methylation of SHOX2 was found
as a highly accurate tumor marker for identifying
patients with lung cancer based on the analysis of bron-
chial aspirates. The hypermethylation of SHOX2 in lung
cancer tissue has otherwise not been described in the
literature so far. The human homeobox gene SHOX2
(short stature homeobox 2, formerly SHOT) is located
on the long arm of chromosome 3 (3q25-q26.1). The
gene - approx. 10 kbp in size - is known to be tran-
scribed in two different isoforms, SHOX2a (993 bp) and
SHOX2b (570 bp) [34], but additional protein-encoding
splice variants may exist (Genbank information). Within
the SHOX2 gene, two large CpG islands could be iden-
tified, with one island covering 1 kbp in the 5’-region
and one 0.5 kbp island in the 3’-region of the gene. So
far, methylation status and impact of these CpG islands
on SHOX2 transcription is not known. Homeobox
genes code for proteins harbouring specific DNA-bind-
ing homeodomains (homeoproteins). They play funda-
mental roles in vertebrate development and
differentiation by acting as transcriptional regulators.
Expression of homeobox proteins themselves is con-
trolled both on the transcriptional and translational
level. SHOX2 is a known regulator of chondrocyte
hypertrophy and has important functions in skeleton
development and embryogenic pattern formation [35].
Other regulatory functions affect embryonic morpho-
genesis, heart and nervous system development [34].
Although most of its known functions are linked to
early events in human development, SHOX2 seems to
be widely expressed in different organs and tissues.
Interestingly, SHOX2 expression is frequent in various
different types of tumors, among them neuroblastomas
[36], breast cancer [37] and squamous cell carcinomas
of the lung (Genbank information). Homeoproteins are
often found to be deregulated in cancer and both
down- and up-regulation can be linked with tumor
development and progression by activating or repressing
multiple downstream genes, thereby acting as proto-
oncogenes or tumor suppressor genes [38-40]. However,
a direct or indirect implication of SHOX2 as transcrip-
tional regulator during cancerogenesis can be
hypothesized.
A significant number of samples analysed in this study
were selected according to an inconclusive (negative)
cytology result. SHOX2 DNA methylation allowed for
an accurate detection of lung cancer patients even in
this group of cytologically negative patient samples. In
clinical practice, the first bronchoscopy has been found
to identify less than half of the lung cancer patients [2].
Based on these results, the use of the SHOX2 tumor
marker in a confirmatory test for the diagnosis of lung
cancer can be expected to identify more than half of the
remaining lung cancer patients in this population. This
methylation assay may potentially speed up and simplify
the workup for test positive patients by reducing the
need for additional diagnostic procedures.
The SHOX2 methylation level in bronchial aspirates
from patients with stage I disease was found to be lower
than from patients with more advanced malignant dis-
ease leading to a lower sensitivity for stage I patients.
The most likely explanation is the smaller size of the
tumor might result in less malignant cells in the corre-
sponding bronchial aspirate; other confounding factors
like tumor aggressiveness and the relation of the tumor
to the bronchial system need to be considered as well.
Possible explanations are that slower growing tumors
are over-represented in this population, because they are
more likely to be clinically detected at an early stage and
they shed less DNA into the bronchial system due to
their lower aggressiveness.
Table 4 Clinical performance of the SHOX2 DNA methylation biomarker with regards to cytology (only from 523 valid
samples passing the quality criterion)
Cytology Result Cases Total Controls Total Test Positive Cases (Sensitivity [%]) Test Negative Controls (Specificity [%])
All 281 242 190 (68%) 230 (95%)
Unknown 187 180 128 (68%) 171 (95%)
Negative 73 62 45 (62%) 59 (95%)
Suspicious 15 0 12 (80%) -
Positive 6 0 5 (83%) -
Among these 523 patients, cytological results were available from 156 patient samples (62 negative controls, 73 negative, 15 suspicious, and 6 positive cases).
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cancer subtypes on the methylation levels of aspirates
showed that patients with SCLC and NSCLC squamous
cell carcinoma have higher levels of methylation than
patients with adenocarcinoma. There is no obvious
explanation for this phenomenon, but the observation is
in line with other studies [11], which showed a lower
sensitivity of marker panels in adenocarcinoma com-
pared to squamous cell NSCLC. A confounding effect of
the tumor location needs to be considered as centrally
located squamous cell carcinomas are usually easier to
assess via bronchoscope, which makes them likely to
yield more target DNA compared to a peripheral loca-
tion. The rationale and the impact of performance dif-
ferences of histological subtypes require further
investigation.
Ideally, a tumor marker would detect all stages and
histological subtypes equally well. Nevertheless, in
today’s clinical practice the vast majority of patients are
diagnosed with advanced stage disease and a test to
diagnose these patients accurately represents a medical
need, making SHOX2 a clinically useful marker. There-
fore, such assay is proposed as a useful tool for confirm-
ing the presence of malignant lung disease in patients
with suspected lung cancer, especially when the histol-
ogy and cytology results from specimen obtained by
bronchoscopy do not confirm the presence of malignant
lung disease. The assay is currently translated into an
CE marked IVD test for patients undergoing first-time
bronchoscopy for suspected lung cancer. The test result
will be suited for use by physicians as an aid in diagno-
sis of lung cancer adjunct to existing clinical and patho-
logical information. A validation study with an
independent patient population is ongoing.
Conclusions
Hypermethylation of SHOX2 in bronchial aspirates is a
sensitive and specific biomarker for identifying subjects
with lung carcinoma, especially if histological and cyto-
logical findings after bronchoscopy are ambiguous.
Additional material
Additional file 1: Patient information and SHOX2 DNA methylation
data. This excel spreadsheet (.xls) contains the relevant clinical
information (i.e. age, gender, smoking habits, diagnosis, sample type) and
the measured SHOX2 methylation values for each patient.
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